Impatient capital18 Jun 2017 08:27
I noted that Apple had decided against getting the Apple Watch through FDA approval as they didn't want their speed of development hampered by the painfully slow approval process. That for a non-invasive device. However the VR market is one of the next big things and that will rely on sensors in the real world to feed back to the clever software. There appear to be many hi-techs going for the body data but all seem wary of making 'health' claims rather going for 'fitness' assistance = avoiding FDA rules.
Sphere are coming at this from the slowest, most life-critical angle and enduring the slow approval then individual hospital approval process. However they are now building on very small numbers, not yet big enough to get any business guy interested. But where will the competition come from when this technology starts to become essential? Much easier to throw the big bucks at an approved product and integrate that in your whizz bang world for the masses than risk delay and your competitors have a clear run. So my hope is that one or other of the 'very' big boys sees the potential and the others are played on the fear of losing out to the slow FDA alternative. Patient capital would then be nicely rewarded.
My belief is that it is a very small step from Proxima taking/returning arterial blood from the body, to encapsulating the clever analysis chip, along with wireless power and signals and sticking the device directly in-line on an artery. With the most critical situation already approved the roll-out to the masses should be easier.
Enhanced humans (6 million dollar man style) in an enhanced reality world, a scary future that we are heading for inevitably.....
Just speculating wildly as usual!!
Sign In
Follow the stocks
